Immunodeficiency in MS

Analysis of Medical Therapy and History as Risks of Immunodeficiency in Multiple Sclerosis Patients

The purpose of this study is to identify if there is a relationship between multiple sclerosis disease-modifying therapy exposure, immunodeficiencies, and infection risk in subjects living with MS.

The purpose of this study is to identify if there is a relationship between multiple sclerosis disease-modifying therapy exposure, immunodeficiencies, and infection risk in subjects living with MS. By understanding this relationship future studies can be designed to create a model of immunosenescence in multiple sclerosis, which could help healthcare providers to predict and assess health risks. Preventative strategies can then be tested to look for ways to prevent these immune-related risks.

Inclusion Criteria

• One or more immunoglobulin level results and medical history available
• 18 years of age or older at the time of data collection
• Patients with first symptom MS or other isolated demyelinating syndromes, neuromyelitis optica, or rheumatic-associated CNS inflammation

Exclusion Criteria:

• No evidence of CNS autoimmune disease
• Less than 18 years of age at the time of data abstraction
• Undergoing plasma exchange at the time of any lab tests drawn